ArticleCancer medicine2026
Efficacy and Safety of rhIL-11 in the Treatment of Cancer Therapy-Induced Thrombocytopenia: A Multicenter Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveThis real-world study aimed to investigate the cancer therapy-induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in its management.
methodsRetrospective analysis included 12,431 CTIT patients treated with rhIL-11 across 58 Chinese centers (July 2023-June 2024). Multivariate logistic regression analysis identified CTIT risk factors. Treatment outcomes and adverse events (AEs) were assessed.
resultsIndependent CTIT risk factors included advanced age, medical history, prior myelosuppression, tumor type, bone marrow involvement, and previous anti-tumor therapy. RhIL-11 demonstrated significant thrombopoietic effects, with a mean treatment duration of 6.79 ± 2.59 days. Platelet (PLT) recovery to 50 × 10
conclusionThis large-scale real-world study confirms the efficacy and safety of rhIL-11 in CTIT management. Treatment responses vary slightly across patient subgroups, but tolerability remains acceptable. Findings emphasize individualized CTIT strategies and proactive AEs monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.